Monoclonal Antibody Development Targeting PD-1 for Autoimmune Diseases

With the commitment of being your best monoclonal antibody development partner, Creative Biolabs is capable of providing our clients with a variety of customized programmed cell death protein 1 (PD-1) based monoclonal antibody discovery services. Equipped with a team of professional scientists, we have won a good reputation among our worldwide customers for accomplishing numerous challenging projects in this field. In our company, our scientists specialized in various PD-1 studies will work with you to develop the most appropriate strategy that will offer reproducible data for your research.

Introduction to PD-1 in Autoimmune Diseases

PD-1, a key cell surface protein, is critical to mediating the immune responses of the human body. It can be expressed by all kinds of T cells to further regulate many physiological responses, such as autoimmunity, infections, and cancers. Meanwhile, the ligands of PD-1, such as PD-L1 and PD-L2, have been found that can induce antitumor T cell responses against cancers and autoimmune diseases. As a result, the development of such monoclonal antibodies targeting PD-1 or its ligands has aroused much attention in the past few years of studies. The data have suggested that monoclonal antibodies against PD-1 are effective in treating a wide range of cancer types without causing toxic side effects. Besides, recent reports have revealed that PD-1/PD-L1 also plays a significant role in regulating peripheral tolerance and autoimmunity in autoimmune disease models, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Fig.1 The function of PD-1 in promoting T cell responses. (Dai, 2014)

Monoclonal Antibody Development Targeting PD-1 for Autoimmune Diseases

PD-1 is an immune checkpoint inhibitory receptor that belongs to the immunoglobulin superfamily and can be identified on all types of T cells and pro-B cells. Till now, monoclonal antibodies targeting PD-1 or its ligands have been considered as a new class of drugs to treat several types of tumors and autoimmune diseases.

As a global contract research organization, Creative Biolabs works on a broad spectrum of PD-1-targeted monoclonal antibody discovery and development services for the treatment of various autoimmune disease types. We utilize unrivaled, proprietary target selection, antibody design, study data, product candidate, advanced project lifecycle management, as well as real-time data to ensure the ideal outcomes. Nowadays, we have established an advanced monoclonal antibody discovery platform that enables us to offer a series of high-quality products for our worldwide customers.

In our labs, we have generated several monoclonal antibodies against PD-1/PD-L1 pathways. Studies on animal models of RA have indicated that these antibodies have the potential to treat RA and improve patients' outcomes in clinical trials. In addition, equipped with a wealth of knowledge about PD-1/PD-L1 interactions, we can provide the rational design of monoclonal antibodies that disrupt the PD-1/PD-L1 pathway. Furthermore, we also offer one-stop-shop custom antibody development for a certain application such as enzyme-linked immunosorbent assay (ELISA), western blot (WB), flow cytometry (FC), and immunofluorescence (IF).

Creative Biolabs is a leading antibody development company, provides one-stop services from antigen synthesis, research, development, and production. With our antibody generation platforms, we are ready to help you tackle your toughest research challenge. If you are interested in our services, please contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.

Reference

1. Dai, S.; et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cellular immunology. 2014, 290(1): 72-79.

For Research Use Only | Not For Clinical Use